W7 - General Session: Maintaining RAAS Inhibition and Managing Hyperkalemia: Expert Insights into Best HF Patient Care Supported by an Independent Educational Grant from AstraZeneca
4:35 PM - 5:35 PM PT
W7 - General Session: Maintaining RAAS Inhibition and Managing Hyperkalemia: Expert Insights into Best HF Patient Care Supported by an Independent Educational Grant from AstraZeneca
Faculty: Stephen J. Greene, MD – Duke Clinical Research Institute, Duke University School of Medicine
W8 - Research Poster #1: Can Inpatient Heart Failure Nurses Drive Early work up of aTTR Cardiac Amyloidosis with the Use of a Red Flag Screening Tool in the Electronic Health Record?
W8 - Research Poster #6: Where there's a will, there's a way: The relationship among will to live, hope, illness representations, and heart failure self-care
W8 - Best Practice Poster #1: Successful Use of Novel, Non-Invasive Remote Monitoring Technology for Management of a Heart Failure Patient: A Sensinel TM CPM System Case Study
W8 - Best Practice Poster #3: Transforming Documentation to Drive Change: Leveraging Epic Smart Phrases to Improve ARNI Utilization in Heart Failure Care
W8 - Best Practice Poster #6: Implementing a Standardized Blast-Page Workflow to Reduce Emergency Department Throughput Times for LVAD Patients: A Five-Year Quality Improvement Experience
W8 - Best Practice Poster #9: Bridging the Gap: A Best Practice Model for Reducing Heart Failure Readmissions Through Inpatient-Outpatient Collaboration
W8 - Industry Poster #1: Acoramidis Mitigates the Rise in N-terminal Pro-B-type Natriuretic Peptide Levels Observed With Placebo in Patients With Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM
W8 - Industry Poster #2: Association Between Early Increase in Serum Transthyretin With Acoramidis and Long-Term Effects on Heart Failure-Related Health Status in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM
W8 - Industry Poster #3: Long‑Term Benefits With Acoramidis on Serum Transthyretin Concentrations and Kansas City Cardiomyopathy Questionnaire-Overall Summary Score in Patients With Transthyretin Amyloid Cardiomyopathy
Location: Sapphire CD
Poster Presenter: Kellie Walsh, MSN, APRN, FNP-BC – Oregon Health & Science University, OHSU Knight Cardiovascular Institute
5:30 PM - 6:30 PM PT
W8 - Industry Poster #4: Long-Term Clinical Benefits of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy and Early Heart Failure Severity, and Survival Benefits Regardless of Atrial Fibrillation Status
W8 - Industry Poster #6:Pivotal trial: Design and rationale for a remote patient-autonomous peripheral edema monitoring device to reduce hospital readmissions
